Who Is Buying Regeneron? Hedge Fund Activity in 2026

Regeneron Pharmaceuticals is one of the most innovative biotechnology companies in the world, with a track record that few peers can match. The company behind Eylea (the blockbuster eye disease treatment), Dupixent (the immunology juggernaut co-developed with Sanofi), and Libtayo (a checkpoint inhibitor for cancer) has consistently delivered both scientific breakthroughs and financial results. Under the leadership of founder-CEO Leonard Schleifer and chief scientist George Yancopoulos, Regeneron has built one of the deepest pipelines in biotech.

The latest 13F filings show 7 funds buying versus 6 selling, with 5 holding steady across 18 tracked funds. The buy-sell ratio is mildly bullish, but the real story lies in one dramatic exit and the caliber of funds on the buying side.

Regeneron Institutional Snapshot

A 7-to-6 ratio is nearly balanced, but the buyer list includes several high-conviction specialist funds making meaningful increases. The sellers are a mix of quant funds trimming and one complete exit that demands attention.

Who's Buying Regeneron?

Seven funds increased or maintained growing positions in Regeneron this quarter:

Vanguard Group — $6.9B (Increased) Vanguard's massive $6.9 billion position reflects Regeneron's prominence in healthcare indices. The increase continues a multi-quarter trend of growing institutional ownership, driven by both passive inflows and Regeneron's rising market capitalization. At this scale, Vanguard is one of the most important holders of REGN shares.

Fidelity Investments — $1.8B (Increased) Fidelity's active healthcare managers pushed the position to $1.8 billion — a clear vote of confidence. Fidelity's research team has deep relationships across the biotech industry and extensive experience modeling complex pipeline valuations. Their continued accumulation suggests conviction in Regeneron's ability to grow beyond its current blockbuster portfolio.

Appaloosa Management — $758.6M (Increased) David Tepper's Appaloosa significantly increased its Regeneron position to $758.6 million, making it one of the fund's largest healthcare bets. Tepper is known for high-conviction, concentrated positions — this isn't a portfolio filler. Appaloosa's increase signals genuine belief that Regeneron is undervalued relative to its pipeline and cash generation.

Millennium Management — $289.3M (Increased) Millennium's increase to $289.3 million across its pod structure is notable. Multiple portfolio managers within the firm are clearly finding opportunities in REGN, and the aggregate increase suggests broad-based bullish sentiment within one of the world's most sophisticated multi-manager platforms.

Canyon Capital — $126.9M (Increased) Canyon's increase to $126.9 million shows that credit-oriented crossover funds see value in Regeneron's equity. Canyon's analytical framework emphasizes downside protection and margin of safety — their buying suggests they view REGN as offering attractive risk-adjusted returns at current levels.

Citadel Advisors — $110.4M (Increased) Ken Griffin's Citadel bumped its position to $110.4 million. Citadel's multi-strategy approach means this increase could be driven by fundamental, quantitative, or relative-value considerations — but the directional signal is clearly bullish.

Baker Bros Advisors — $104.6M (Increased) Baker Brothers' increase to $104.6 million is one of the most informative signals in this analysis. As the premier biotech-specialist hedge fund, Baker Bros has proprietary scientific expertise that few other investors can match. Their continued buying suggests that Regeneron's clinical pipeline — particularly next-generation Dupixent indications and new antibody programs — has real optionality that the market hasn't fully priced.

Who's Selling Regeneron?

Six funds reduced their exposure, including one high-profile complete exit:

State Street — $3.6B (Decreased) State Street trimmed its position but still holds $3.6 billion — an enormous stake. This is likely driven by index rebalancing and fund flow dynamics rather than a bearish fundamental view. At $3.6 billion, State Street remains one of the largest holders of REGN shares.

Two Sigma — $214.2M (Decreased) The quantitative powerhouse reduced to $214.2 million. Two Sigma's model-driven approach means position changes are responsive to short-term statistical patterns and risk parameters. The fund still maintains a very substantial position, suggesting their models see ongoing value in the name.

D.E. Shaw — $118.4M (Decreased) Another major quant fund trimmed to $118.4 million. The fact that both Two Sigma and D.E. Shaw reduced simultaneously could indicate that quantitative momentum signals are less favorable in the near term, even as fundamental investors continue buying.

Bridgewater Associates — $55.4M (Decreased) Bridgewater reduced to $55.4 million, consistent with the macro fund's generally modest pharmaceutical allocations. This reduction has more to do with Bridgewater's macro positioning than with any view specific to Regeneron.

Renaissance Technologies — $6.9M (Decreased) Renaissance reduced to a very small $6.9 million position, essentially a residual holding. This signals that the quant firm's models have moved away from REGN in the near term, though they haven't exited entirely.

Himalaya Capital — SOLD ENTIRE POSITION This is the quarter's headline exit. Himalaya Capital, the value-oriented fund led by Li Lu (sometimes called "the Chinese Warren Buffett"), completely liquidated its Regeneron position. Li Lu is known for extremely concentrated, long-term holdings, so a complete exit is a significant event. This could signal that Himalaya believes Regeneron has reached fair value, or that they've found more attractive opportunities elsewhere.

Notable Moves

Himalaya Capital's complete exit is the most dramatic move this quarter. Li Lu rarely trades — his investment philosophy emphasizes buying wonderful businesses and holding them for years. A full exit from Regeneron suggests he believes the stock has reached or exceeded his intrinsic value estimate. Given his reputation as one of the world's most disciplined value investors, this deserves serious attention from any REGN shareholder.

On the flip side, Appaloosa's $758.6 million position represents one of the largest hedge fund bets on Regeneron. David Tepper and Li Lu represent very different investment philosophies — Tepper is more opportunistic and willing to bet on momentum, while Li Lu is a pure value investor. Their divergence on Regeneron suggests a genuine debate about the stock's valuation.

Baker Bros' continued buying is the strongest fundamental signal for bulls. No fund in the world has better biotech pipeline expertise, and their consistent accumulation through multiple quarters suggests they see clinical catalysts that the broader market hasn't fully appreciated.

The quant fund consensus is mixed: D.E. Shaw and Two Sigma trimmed while Renaissance reduced to a stub, but Millennium increased. This divergence among quant funds suggests there's no clear statistical edge in either direction in the near term.

What This Signals

Regeneron presents a genuine institutional debate, with credible investors on both sides:

The bull case is pipeline-driven. Buyers like Baker Bros, Appaloosa, and Fidelity are betting that Regeneron's pipeline — including Dupixent line extensions, next-generation Eylea, and novel antibody programs — can drive the next leg of growth. The company's scientific capabilities are world-class, and its R&D productivity is among the highest in the industry.

The bear case is valuation-driven. Himalaya Capital's exit and State Street's trim suggest some investors believe Regeneron's current stock price already reflects much of the pipeline's potential. With Eylea facing biosimilar competition and Dupixent's growth potentially plateauing, the margin of safety may be shrinking for pure value investors.

Fundamental versus quantitative divergence. The most interesting pattern is the split between fundamental investors (mostly buying) and quantitative funds (mostly selling). This often signals that the stock's near-term price action may be choppy, but the longer-term fundamental trajectory is constructive.

Cash generation remains a moat. Regeneron generates enormous free cash flow, giving it the financial flexibility to fund its pipeline without dilution. This cash fortress makes it attractive to funds like Canyon and Appaloosa that emphasize downside protection.

Watch the Dupixent trajectory. Dupixent is the key swing factor. If upcoming label expansions (COPD, food allergy, additional atopic conditions) succeed, Regeneron could significantly exceed current consensus estimates. If growth disappoints, the sellers will be proven right.

For individual investors, the institutional picture is constructive but contested. The strongest signal comes from Baker Bros' continued accumulation — when the world's best biotech fund keeps buying, the pipeline likely has more value than the market appreciates.

---

Track REGN institutional activity and portfolio changes in real time at app.freenance.io/smart-money/ticker/REGN.

Related Articles

• Who Is Buying Moderna? Hedge Fund Activity in 2026
• Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
• Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026

FAQ

What is the Eylea franchise and why does it matter for Regeneron?

Eylea is Regeneron's blockbuster treatment for wet age-related macular degeneration and other retinal diseases, and it has historically been one of the company's most important revenue drivers. With Eylea now facing biosimilar competition, institutional investors are closely watching the transition to Eylea HD, which influenced Himalaya Capital's decision to fully exit the position.

How does Dupixent factor into the institutional thesis?

Dupixent, co-developed with Sanofi, is the immunology franchise that has become Regeneron's primary growth engine, treating atopic dermatitis, asthma, and several emerging indications. Funds buying REGN — including Baker Bros and Fidelity — are betting that label expansions in COPD, food allergy, and additional atopic conditions can extend Dupixent's growth runway materially.

What does Regeneron's oncology pipeline look like?

Regeneron's oncology efforts centre on Libtayo (a PD-1 checkpoint inhibitor) and a deep pipeline of bispecific antibodies targeting blood cancers and solid tumours. Baker Bros Advisors' continued accumulation is widely interpreted as a vote of confidence in Regeneron's R&D productivity and the optionality embedded in these clinical programs.

Why is Himalaya Capital's full exit considered significant?

Li Lu's Himalaya Capital is known for extremely concentrated, multi-year holdings, so a complete exit is a notable event. It signals that one of the world's most disciplined value investors believes REGN has reached or exceeded his estimate of intrinsic value, which is a useful counterweight to the bullish accumulation by specialist biotech funds.

Is this article investment advice on Regeneron stock?

No. This page summarises publicly disclosed 13F filings for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation. Always consult official filings and a licensed advisor before making any investment decision.